REPL / Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch

Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous s more_horizontal

The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from more_horizontal

Replimune (REPL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agre more_horizontal

Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound more_horizontal

Replimune Group, Inc. (REPL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit fro more_horizontal

Today, we revisit an intriguing oncology developmental company called Replimune Group, Inc. for the first time in more than a year. This week the comp more_horizontal

Following a stronger-than-expected jobs report for June, U.S. market indexes rose on Friday as investors anticipate the Federal Reserve will continue more_horizontal